MTOA-TFSI

目录号: HY-W008870: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

MTOA-TFSI 是一种具有高多孔性和导电性的离子液体,可用于电化学力学应变 (ECMS) 研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

MTOA-TFSI Chemical Structure

CAS No. : 375395-33-8

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 g	￥220	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MTOA-TFSI 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

MTOA-TFSI is an ionic liquid with high porosity and conductivity, which can be used in electrochemical mechanical strain (ECMS) studies^[1].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
786-0	GI₅₀	0.415 μM Compound: 5, NSC-747259	Growth inhibition of human 786-0 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human 786-0 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
A498	GI₅₀	1.82 μM Compound: 5, NSC-747259	Growth inhibition of human A498 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human A498 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
A549	GI₅₀	1.9 μM Compound: 5, NSC-747259	Growth inhibition of human A549 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human A549 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
ACHN	GI₅₀	0.63 μM Compound: 5, NSC-747259	Growth inhibition of human ACHN cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human ACHN cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
BT-549	GI₅₀	0.421 μM Compound: 5, NSC-747259	Growth inhibition of human BT549 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human BT549 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
CCRF-CEM	GI₅₀	0.19 μM Compound: 5, NSC-747259	Growth inhibition of human CCRF-CEM cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human CCRF-CEM cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
COLO 205	GI₅₀	0.292 μM Compound: 5, NSC-747259	Growth inhibition of human COLO205 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human COLO205 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
DU-145	GI₅₀	0.407 μM Compound: 5, NSC-747259	Growth inhibition of human DU145 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human DU145 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
EKVX	GI₅₀	0.215 μM Compound: 5, NSC-747259	Growth inhibition of human EKVX cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human EKVX cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HCC 2998	GI₅₀	0.425 μM Compound: 5, NSC-747259	Growth inhibition of human HCC2998 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HCC2998 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HCT-116	GI₅₀	0.319 μM Compound: 5, NSC-747259	Growth inhibition of human HCT116 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HCT116 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HCT-15	GI₅₀	0.993 μM Compound: 5, NSC-747259	Growth inhibition of human HCT15 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HCT15 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HL-60(TB)	GI₅₀	0.173 μM Compound: 5, NSC-747259	Growth inhibition of human HL-60(TB) cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HL-60(TB) cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HOP-62	GI₅₀	0.787 μM Compound: 5, NSC-747259	Growth inhibition of human HOP62 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HOP62 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HOP-92	GI₅₀	0.206 μM Compound: 5, NSC-747259	Growth inhibition of human HOP92 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HOP92 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
Hs-578T	GI₅₀	0.417 μM Compound: 5, NSC-747259	Growth inhibition of human Hs 578T cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human Hs 578T cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HT-29	GI₅₀	0.305 μM Compound: 5, NSC-747259	Growth inhibition of human HT-29 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HT-29 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
IGROV-1	GI₅₀	0.388 μM Compound: 5, NSC-747259	Growth inhibition of human IGROV1 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human IGROV1 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
K562	GI₅₀	0.186 μM Compound: 5, NSC-747259	Growth inhibition of human K562 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human K562 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
KM12	GI₅₀	0.31 μM Compound: 5, NSC-747259	Growth inhibition of human KM12 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human KM12 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
LOX IMVI	GI₅₀	0.192 μM Compound: 5, NSC-747259	Growth inhibition of human LOXIMVI cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human LOXIMVI cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
M14	GI₅₀	0.453 μM Compound: 5, NSC-747259	Growth inhibition of human M14 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human M14 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
Malme-3M	GI₅₀	0.29 μM Compound: 5, NSC-747259	Growth inhibition of human MALME-3M cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MALME-3M cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MCF7	GI₅₀	0.317 μM Compound: 5, NSC-747259	Growth inhibition of human MCF7 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MCF7 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MDA-MB-231	GI₅₀	0.345 μM Compound: 5, NSC-747259	Growth inhibition of human MDA-MB-231 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MDA-MB-231 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MDA-MB-435	GI₅₀	0.335 μM Compound: 5, NSC-747259	Growth inhibition of human MDA-MB-435 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MDA-MB-435 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MDA-MB-468	GI₅₀	0.119 μM Compound: 5, NSC-747259	Growth inhibition of human MDA-MB-468 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MDA-MB-468 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MOLT-4	GI₅₀	0.324 μM Compound: 5, NSC-747259	Growth inhibition of human MOLT4 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MOLT4 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI/ADR-RES	GI₅₀	1.68 μM Compound: 5, NSC-747259	Growth inhibition of human NCI/ADR-RES cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI/ADR-RES cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H226	GI₅₀	0.478 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H226 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H226 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H23	GI₅₀	0.308 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H23 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H23 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H322M	GI₅₀	1.81 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H322M cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H322M cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H460	GI₅₀	0.362 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H460 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H460 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H522	GI₅₀	0.287 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H522 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H522 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
OVCAR-3	GI₅₀	0.315 μM Compound: 5, NSC-747259	Growth inhibition of human OVCAR-3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human OVCAR-3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
OVCAR-4	GI₅₀	0.309 μM Compound: 5, NSC-747259	Growth inhibition of human OVCAR4 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human OVCAR4 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
OVCAR-5	GI₅₀	1.24 μM Compound: 5, NSC-747259	Growth inhibition of human OVCAR5 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human OVCAR5 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
OVCAR-8	GI₅₀	0.468 μM Compound: 5, NSC-747259	Growth inhibition of human OVCAR8 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human OVCAR8 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
PC-3	GI₅₀	0.282 μM Compound: 5, NSC-747259	Growth inhibition of human PC3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human PC3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
RPMI-8226	GI₅₀	0.046 μM Compound: 5, NSC-747259	Growth inhibition of human RPMI8226 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human RPMI8226 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
RXF 393	GI₅₀	0.464 μM Compound: 5, NSC-747259	Growth inhibition of human RFX393 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human RFX393 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SF-268	GI₅₀	0.493 μM Compound: 5, NSC-747259	Growth inhibition of human SF268 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SF268 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SF-295	GI₅₀	0.333 μM Compound: 5, NSC-747259	Growth inhibition of human SF295 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SF295 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SF-539	GI₅₀	0.514 μM Compound: 5, NSC-747259	Growth inhibition of human SF539 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SF539 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SK-MEL-2	GI₅₀	0.356 μM Compound: 5, NSC-747259	Growth inhibition of human SK-MEL-2 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SK-MEL-2 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SK-MEL-28	GI₅₀	0.71 μM Compound: 5, NSC-747259	Growth inhibition of human SK-MEL-28 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SK-MEL-28 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SK-MEL-5	GI₅₀	0.177 μM Compound: 5, NSC-747259	Growth inhibition of human SK-MEL-5 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SK-MEL-5 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SK-OV-3	GI₅₀	0.565 μM Compound: 5, NSC-747259	Growth inhibition of human SKOV3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SKOV3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SN12C	GI₅₀	0.367 μM Compound: 5, NSC-747259	Growth inhibition of human SN12C cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SN12C cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SNB-19	GI₅₀	0.587 μM Compound: 5, NSC-747259	Growth inhibition of human SNB19 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SNB19 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SNB-75	GI₅₀	0.336 μM Compound: 5, NSC-747259	Growth inhibition of human SNB75 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SNB75 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SR	GI₅₀	0.162 μM Compound: 5, NSC-747259	Growth inhibition of human SR cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SR cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SW-620	GI₅₀	0.378 μM Compound: 5, NSC-747259	Growth inhibition of human SW620 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SW620 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
T47D	GI₅₀	0.428 μM Compound: 5, NSC-747259	Growth inhibition of human T47D cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human T47D cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
TK-10	GI₅₀	0.503 μM Compound: 5, NSC-747259	Growth inhibition of human TK10 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human TK10 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
U-251	GI₅₀	0.334 μM Compound: 5, NSC-747259	Growth inhibition of human U251 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human U251 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
UACC-257	GI₅₀	0.411 μM Compound: 5, NSC-747259	Growth inhibition of human UACC257 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human UACC257 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
UACC-62	GI₅₀	0.335 μM Compound: 5, NSC-747259	Growth inhibition of human UACC62 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human UACC62 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
UO-31	GI₅₀	0.686 μM Compound: 5, NSC-747259	Growth inhibition of human UO31 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human UO31 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]

分子量

648.85

Formula

C₂₇H₅₄F₆N₂O₄S₂

CAS 号

375395-33-8

性状

粘稠液体

颜色

Colorless to light yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

纯度 & 产品资料

纯度: ≥95.0%

选择批次：

Data Sheet (519 KB) SDS (392 KB)

COA (186 KB) HNMR (122 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Yamato K, et al. Stability of electrochemomechanical strains in polypyrrole films using ionic liquids. Synthetic metals, 2009, 159(9-10): 839-842.

MTOA-TFSI 相关分类

Others

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量		浓度		体积		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)	×	体积 _(start)	=	浓度 _(final)	×	体积 _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MTOA-TFSI375395-33-8Biochemical Assay Reagentsbiochemical assayreagentInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MTOA-TFSI

Customer Review

MTOA-TFSI 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

MTOA-TFSI 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

MTOA-TFSI

Customer Review

MTOA-TFSI 相关抗体

MTOA-TFSI 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

MTOA-TFSI 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z